Hyperbaric High Pressure Oxygen Therapy in Post-COVID Syndrome and ME/CFS

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

July 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Post-COVID ME/CFS
Interventions
COMBINATION_PRODUCT

Hyperbaric oxygen therapy (HBOT)

"HBOT is a medical treatment employed for various conditions. It entails breathing 100% oxygen within a pressurized chamber known as a hyperbaric chamber. This oxygen-rich environment promotes healing and aids in combating specific infections.~In this study, the investigators will administer HBOT using a hyperbaric chamber set to 2 times the normal atmospheric pressure, indicated as 2 atmosphere absolute (ATA). This pressure surge enhances oxygen dissolution into the bloodstream, surpassing levels achievable at sea level. The pressure will be raised incrementally, followed by HBOT sessions lasting for a total of 90 minutes. The 90-minute sessions include brief 5-minute intervals for ambient air every 20 minutes to ensure safety and comfort. Treatment will be conducted five days a week over eight weeks.~Supervised by competent healthcare professionals, HBOT is considered safe, with potential side effects primarily stemming from heightened pressure and, in rare cases, oxygen toxicity."

Trial Locations (1)

10117

RECRUITING

Charité - Universitätsmedizin Berlin, Berlin

All Listed Sponsors
collaborator

KLINIK BAVARIA Kreischa

UNKNOWN

collaborator

Vivantes Klinikum im Friedrichshain

UNKNOWN

lead

Charite University, Berlin, Germany

OTHER